Susquehanna Fundamental Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-43,140	Closed	-$7.92M	–	1983
2021 Q2	$7.92M	Buy	43,140 +3,055	+8%	+$524K	0.14%	185
2021 Q1	$6.13M	Hold	40,085	–	–	0.11%	271
2020 Q4	$6.26M	Buy	40,085 +8,938	+29%	+$1.15M	0.11%	245
2020 Q3	$3.56M	Sell	31,147 -1,653	-5%	-$178K	0.11%	255
2020 Q2	$3.68M	Buy	+32,800	New	+$3.48M	0.18%	142

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Susquehanna Fundamental Investments's ALXN Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 43,140 shares — an estimated $7.92M sold.

Susquehanna Fundamental Investments first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $7.92M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Susquehanna Fundamental Investments reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Susquehanna Fundamental Investments sold 43,140 Alexion Pharmaceuticals shares in Q3 2021, an estimated $7.92M.
Susquehanna Fundamental Investments first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
Susquehanna Fundamental Investments's Alexion Pharmaceuticals position peaked at $7.92M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.